Literature DB >> 23158137

Tumorigenesis and spontaneous metastasis by luciferase-labeled human xenograft osteosarcoma cells in nude mice.

Lin Du1, Wen-ting Xu, Qi-ming Fan, Bing Tu, Yang Shen, Wei Yan, Ting-ting Tang, You Wang.   

Abstract

BACKGROUND: Osteosarcoma (OS) is the most common primary malignant tumor of bone. Mouse models of human OS can invariably provide greater insight into the complex mechanisms that underlie the development and pathogenesis of this aggressive tumor. Bioluminescence technology favored tracing cancer cells in vivo. In this study, an OS model was described and evaluated using human OS cell line, Saos2, labeled with luciferase (Saos2-luc).
METHODS: Saos2 cells were infected by lentivirus loading a firefly luciferase gene. Luciferase expression of Saos2-luc cells was characterized both in vitro and in vivo. Specific biologic and oncologic features of Saos2-luc cells were analyzed. The OS was established as orthotopic xenografts in nude mice. Both orthotopic tumors and spontaneous lung metastasis were analyzed.
RESULTS: Tumorigenesis and spontaneous lung metastasis in nude mice could be monitored in vivo through in vivo imaging system. The enhancement in proliferation, migration and invasion abilities and the attenuation in adhesion ability were observed in Saos2-luc cells compared with Saos2 cells. Furthermore, there were the up-regulation of Osteocalcin, CCR10, CXCR1 and ID1 and the down-regulation of ALP, collagen I, CCR1, CCR3, CXCR3, NID and N-cadherin in Saos2-luc cells compare to Saos2 cells. The rate of spontaneous lung metastasis in Saos2-luc cells was higher than that in Saos2 cells, although without significant difference.
CONCLUSIONS: Lentivirus transfection may cause alteration of gene expression profiles and further biological functions. This model can be used in the elucidation of molecular mechanisms of tumorigenesis and the screening of new therapeutic agents.

Entities:  

Mesh:

Year:  2012        PMID: 23158137

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  7 in total

1.  Establishment and characterization of a new highly metastatic human osteosarcoma cell line derived from Saos2.

Authors:  Lin Du; Qiming Fan; Bing Tu; Wei Yan; Tingting Tang
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

2.  Human tumor xenograft models for preclinical assessment of anticancer drug development.

Authors:  Joohee Jung
Journal:  Toxicol Res       Date:  2014-03

3.  TIMP3 Overexpression Improves the Sensitivity of Osteosarcoma to Cisplatin by Reducing IL-6 Production.

Authors:  Xiu-Guo Han; Hui-Min Mo; Xu-Qiang Liu; Yan Li; Lin Du; Han Qiao; Qi-Ming Fan; Jie Zhao; Shu-Hong Zhang; Ting-Ting Tang
Journal:  Front Genet       Date:  2018-04-20       Impact factor: 4.599

4.  CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis.

Authors:  Lin Du; Xiu-Guo Han; Bing Tu; Min-Qi Wang; Han Qiao; Shu-Hong Zhang; Qi-Ming Fan; Ting-Ting Tang
Journal:  Cell Death Dis       Date:  2018-06-18       Impact factor: 8.469

5.  PLA2G16 promotes osteosarcoma metastasis and drug resistance via the MAPK pathway.

Authors:  Lin Li; Shoulei Liang; Amanda R Wasylishen; Yanqin Zhang; Xueli Yang; Bingzheng Zhou; Luling Shan; Xiuxin Han; Tianyang Mu; Guowen Wang; Shunbin Xiong
Journal:  Oncotarget       Date:  2016-04-05

6.  Tracking Tumor Colonization in Xenograft Mouse Models Using Accelerator Mass Spectrometry.

Authors:  Nicholas R Hum; Kelly A Martin; Michael A Malfatti; Kurt Haack; Bruce A Buchholz; Gabriela G Loots
Journal:  Sci Rep       Date:  2018-10-09       Impact factor: 4.379

7.  Two Beats One: Osteosarcoma Therapy with Light-Activated and Chemo-Releasing Keratin Nanoformulation in a Preclinical Mouse Model.

Authors:  Elisa Martella; Barbara Dozza; Claudia Ferroni; Clement Osuru Obeyok; Andrea Guerrini; Daniele Tedesco; Ilse Manet; Giovanna Sotgiu; Marta Columbaro; Marco Ballestri; Lucia Martini; Milena Fini; Enrico Lucarelli; Greta Varchi; Serena Duchi
Journal:  Pharmaceutics       Date:  2022-03-19       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.